Stemline Therapeutics

Representative image showing a modern breast cancer consultation as Menarini’s elacestrant and capivasertib data raise fresh questions about oral targeted therapy in metastatic disease.

Pharma & Biotech

Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations

by Pallavi Madhiraju
May 30, 2026
0 Comments

Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?

Read More

Representative image of advanced breast cancer research, reflecting Menarini Group’s ASCO 2026 elacestrant data and the growing focus on targeted treatment combinations for ER-positive, HER2-negative metastatic breast cancer.

Pharma & Biotech

ASCO 2026: Menarini’s elacestrant program expands the fight against endocrine resistance

by Pallavi Madhiraju
May 28, 2026
0 Comments

Find out how Menarini’s elacestrant data at ASCO 2026 could reshape ER-positive metastatic breast cancer treatment.

Read More